Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw ...

The Trump administration's healthcare policy changes from the gutting of medical research grants to changes on the CDC vaccine board were the focus of the discussion on the latest episode of the ...

Rural hospitals are facing growing cybersecurity threats and digital demands but often lack the resources to respond — a gap ...

Abeona Therapeutics makes Zevaskyn by engineering a patient’s biopsied skin cells to express the collagen that they lack, then growing those cells into sheets that can be surgically applied to a ...

June has seen a slew of executive hires, promotions, exits and layoffs across the healthcare sector. For example, CVS Health ...

The Supreme Court upheld the constitutionality of an Affordable Care Act provision requiring insurance coverage of certain preventive services without cost-sharing. Many healthcare leaders applauded ...

Hinge Health and Omada Health. During a recent panel discussion, venture capitalists shared lessons learned about health tech ...

If you or someone you love is ready to seek help for substance use, outpatient treatment can be a practical and effective choice. It allows you to maintain your daily responsibilities while ...

The insurers made commitments to six actions, according to AHIP: Standardizing electronic prior authorization: The health plans will develop standardized data and submission requirements for ...

The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high. Your varicose or spider veins ...

The company — which for now, operates only in Florida — seeks to improve pediatric care access in underserved areas by building practices in these neighborhoods and accepting all insurance ...

—Actio Biosciences raised $66 million for clinical development of its two lead programs, both oral small molecules. ABS-1230 is a KCNT1 inhibitor on track to start Phase 1 testing later this ...